Michaela Dostalova Merkerova

9PUBLICATIONS
17CO-AUTHORS
Haematological tumoursPredictive and prognostic markersRegenerative medicine (incl. stem cells)Medical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jan 05, 2024
Attenuated cell cycle and DNA damage response transcriptome signatures and overrepresented cell adhesion processes imply accelerated progression in patients with lower-risk myelodysplastic neoplasms.

Monika Kaisrlikova, David Kundrat, Pavla Koralkova

|Jul 06, 2023
Expression of circular RNAs in myelodysplastic neoplasms and their association with mutations in the splicing factor gene SF3B1.

Iva Trsova, Andrea Hrustincova, Zdenek Krejcik

|May 03, 2022
RUNX1 mutations contribute to the progression of MDS due to disruption of antitumor cellular defense: a study on patients with lower-risk MDS.

Monika Kaisrlikova, Jitka Vesela, David Kundrat

|May 05, 2021
Low Plasma Citrate Levels and Specific Transcriptional Signatures Associated with Quiescence of CD34+ Progenitors Predict Azacitidine Therapy Failure in MDS/AML Patients.

Pavla Koralkova, Monika Belickova, David Kundrat

|Jan 12, 2021
Modulation of the Immune Response by Deferasirox in Myelodysplastic Syndrome Patients.

Hana Votavova, Zuzana Urbanova, David Kundrat

|Sep 26, 2020
LncRNA Profiling Reveals That the Deregulation of H19, WT1-AS, TCL6, and LEF1-AS1 Is Associated with Higher-Risk Myelodysplastic Syndrome.

Katarina Szikszai, Zdenek Krejcik, Jiri Klema

Pageof 2

Frequent Collaborators

6 joint publications

Monika Belickova

3 joint publications

Vladimir Divoky

2 joint publications

Jiri Klema

2 joint publications

Pavla Koralkova